cnbc.com / .cnbc-com-health-care

Club holding Lilly stock slumped 1% Tuesday while Novo Nordisk shares jumped nearly 9%.

The FDA on Monday approved the first-ever GLP-1 pill from the Danish pharmaceutical giant.

FDA approves first GLP-1 pill for obesity from Novo Nordisk

Trump's pot executive order follows a yearlong industry push blending lobbying, donations and insider access, opening the door to a Medicare CBD pilot.

The company said it has adopted 23 ongoing "action plans" to track and implement recommended improvements, all of which will be completed by the end of March.

Dealmakers expected a flood of M&A to take place in 2025 following the election of President Trump. The number of transactions didn't live up to the hype.

President Donald Trump signed an executive order Thursday reclassifying marijuana as a Schedule III substance with looser restrictions.

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity.

Medline priced at $29 per share on Tuesday, raising $6.26 billion to cap off a strong year for new listings and bolster optimism about 2026.

2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.